AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Views & Reviews
October 14, 2020

Idiopathic distal sensory polyneuropathy
ACTTION diagnostic criteria

Roy Freeman, MD https://orcid.org/0000-0003-3976-6022, Jennifer S. Gewandter, PhD, MPH https://orcid.org/0000-0001-7938-6775, Catharina G. Faber, MD, PhD, Christopher Gibbons, MD https://orcid.org/0000-0003-0087-5336, Simon Haroutounian, PhD https://orcid.org/0000-0003-2231-5452, Giuseppe Lauria, MD https://orcid.org/0000-0001-9773-020X, Todd Levine, MD, … Show All … , Rayaz A. Malik, MBChB, PhD, J. Robinson Singleton, MD, A. Gordon Smith, MD, Josh Bell, MD, PhD, Robert H. Dworkin, PhD https://orcid.org/0000-0002-9464-5488, Eva Feldman, MD, PhD https://orcid.org/0000-0002-9162-2694, David N. Herrmann, MBBCh, Ahmet Hoke, MD, PhD https://orcid.org/0000-0003-1215-3373, Noah Kolb, MD https://orcid.org/0000-0003-2651-2349, Heikki Mansikka, MD, Anne Louise Oaklander, MD, PhD https://orcid.org/0000-0002-9578-1596, Amanda Peltier, MD https://orcid.org/0000-0003-1097-7715, Michael Polydefkis, MD https://orcid.org/0000-0002-7584-7447, Elissa Ritt, DHSc, James W. Russell, MBChB, Stephen Sainati, MD, PhD, Deborah Steiner, MD, Roi Treister, PhD https://orcid.org/0000-0002-5624-2995, and Nurcan Üçeyler, MD https://orcid.org/0000-0001-6973-6428Authors Info & Affiliations
December 1, 2020 issue
95 (22) 1005-1014
https://doi.org/10.1212/WNL.0000000000010988
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objective

To present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research.

Methods

The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria.

Results

An iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs.

Conclusion

Adoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

References

1.
Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016;31:5–20.
Crossref
PubMed
Google Scholar
2.
de Greef BTA, Hoeijmakers JGJ, Gorissen-Brouwers CML, Geerts M, Faber CG, Merkies ISJ. Associated conditions in small fiber neuropathy - a large cohort study and review of the literature. Eur J Neurol 2018;25:348–355.
Crossref
PubMed
Google Scholar
3.
Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008;131:1912–1925.
Crossref
PubMed
Google Scholar
4.
Samuelsson K, Kostulas K, Vrethem M, Rolfs A, Press R. Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for Fabry disease. J Clin Neurol 2014;10:108–118.
Crossref
PubMed
Google Scholar
5.
Peters MJ, Bakkers M, Merkies IS, Hoeijmakers JG, van Raak EP, Faber CG. Incidence and prevalence of small-fiber neuropathy: a survey in The Netherlands. Neurology 2013;81:1356–1360.
Crossref
PubMed
Google Scholar
6.
Bednarik J, Vlckova-Moravcova E, Bursova S, Belobradkova J, Dusek L, Sommer C. Etiology of small-fiber neuropathy. J Peripher nervous Syst : JPNS 2009;14:177–183.
Crossref
PubMed
Google Scholar
7.
Lacomis D. Small-fiber neuropathy. Muscle & nerve 2002;26:173–188.
Crossref
PubMed
Google Scholar
8.
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes care 2010;33:2285–2293.
Crossref
PubMed
Google Scholar
9.
England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American academy of neurology, the American association of electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology 2005;64:199–207.
Crossref
PubMed
Google Scholar
10.
Devigili G, Rinaldo S, Lombardi R, et al. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain 2019;142:3728–3736.
Crossref
PubMed
Google Scholar
11.
Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy: a review. JAMA Neurol 2019;76:1240–1251.
Crossref
PubMed
Google Scholar
12.
Haroutounian S, Todorovic MS, Leinders M, Campagnalo M, Gewandter JS, Dworkin RH, Freeman R. Diagnostic criteria for idiopathic small fiber neuropathy: a systematic review. Muscle and Nerve. Epub 2020 September 29.
Google Scholar
13.
ACTTION CONCEPPT Website. Available at: acttion.org/conceppt. Accessed August 21, 2020.
Google Scholar
14.
Abraira VE, Ginty DD. The sensory neurons of touch. Neuron 2013;79:618–639.
Crossref
PubMed
Google Scholar
15.
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267–284.
Crossref
PubMed
Google Scholar
16.
Bourane S, Grossmann KS, Britz O, et al. Identification of a spinal circuit for light touch and fine motor control. Cell 2015;160:503–515.
Crossref
PubMed
Google Scholar
17.
Ochoa JL, Torebjork HE. Paraesthesiae from ectopic impulse generation in human sensory nerves. Brain 1980;103:835–853.
Crossref
PubMed
Google Scholar
18.
Lennertz RC, Tsunozaki M, Bautista DM, Stucky CL. Physiological basis of tingling paresthesia evoked by hydroxy-alpha-sanshool. J Neurosci 2010;30:4353–4361.
Crossref
PubMed
Google Scholar
19.
Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci 2010;11:823–836.
Crossref
PubMed
Google Scholar
20.
Zimmerman A, Bai L, Ginty DD. The gentle touch receptors of mammalian skin. Science 2014;346:950–954.
Crossref
PubMed
Google Scholar
21.
Lallemend F, Ernfors P. Molecular interactions underlying the specification of sensory neurons. Trends Neurosci 2012;35:373–381.
Crossref
PubMed
Google Scholar
22.
Gewandter JS, Gibbons CH, Campagnolo M, et al. Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTTION systematic review. Neurology 2019;93:346–360.
Crossref
PubMed
Google Scholar
23.
Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157:1599–1606.
Crossref
PubMed
Google Scholar
24.
Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229–239.
Crossref
PubMed
Google Scholar
25.
England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the AAN, AANEM, and AAPMR. Neurology 2009;72:185–192.
Crossref
PubMed
Google Scholar
26.
Martina ISJ, van Koningsveld R, Schmitz PIM, et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosur Ps 1998;65:743–747.
Crossref
PubMed
Google Scholar
27.
Farhad K, Traub R, Ruzhansky KM, Brannagan TH III. Causes of neuropathy in patients referred as "idiopathic neuropathy. Muscle Nerve 2016;53:856–861.
Crossref
PubMed
Google Scholar
28.
Lang M, Treister R, Oaklander AL. Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. J Neurol 2016;263:2515–2527.
Crossref
PubMed
Google Scholar
29.
Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001;57:1701–1704.
Crossref
PubMed
Google Scholar
30.
Plante-Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol 2018;265:976–983.
Crossref
PubMed
Google Scholar
31.
Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71:26–39.
Crossref
PubMed
Google Scholar
32.
Han C, Hoeijmakers JG, Liu S, et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain 2012;135:2613–2628.
Crossref
PubMed
Google Scholar
33.
Huang J, Yang Y, Zhao P, et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci 2013;33:14087–14097.
Crossref
PubMed
Google Scholar
34.
Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A 2012;109:19444–19449.
Crossref
PubMed
Google Scholar
35.
Huang J, Han C, Estacion M, et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain 2014;137:1627–1642.
Crossref
PubMed
Google Scholar
36.
Cazzato D, Lauria G. Small fibre neuropathy. Curr Opin Neurol 2017;30:490–499.
Crossref
PubMed
Google Scholar
37.
Wadhawan S, Pant S, Golhar R, et al. NaV channel variants in patients with painful and nonpainful peripheral neuropathy. Neurol Genet 2017;3:e207.
Crossref
PubMed
Google Scholar
38.
Blesneac I, Themistocleous AC, Fratter C, et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain 2018;159:469–480.
Crossref
PubMed
Google Scholar
39.
Alsaloum M, Estacion M, Almomani R, et al. A gain-of-function sodium channel beta2-subunit mutation in painful diabetic neuropathy. Mol Pain 2019;15:1744806919849802.
Crossref
Google Scholar
40.
Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain 2019;160:19–27.
Crossref
PubMed
Google Scholar
41.
Fillingim RB, Bruehl S, Dworkin RH, et al. The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. J pain : official J Am Pain Soc 2014;15:241–249.
Crossref
PubMed
Google Scholar
42.
Lauria G, Bakkers M, Schmitz C, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nervous Syst 2010;15:202–207.
Crossref
PubMed
Google Scholar
43.
Provitera V, Gibbons CH, Wendelschafer-Crabb G, et al. A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. Eur J Neurol 2016;23:333–338.
Crossref
PubMed
Google Scholar
44.
Dillingham T, Chen S, Andary M, et al. Establishing high-quality reference values for nerve conduction studies: a report from the normative data task force of the American Association of Neuromuscular & Electrodiagnostic Medicine. Muscle & nerve 2016;54:366–370.
Crossref
PubMed
Google Scholar
45.
Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005;12:747–758.
Crossref
PubMed
Google Scholar
46.
Dyck PJ, O'Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. Muscle & nerve 1999;22:659–662.
Crossref
PubMed
Google Scholar
47.
Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006;123:231–243.
Crossref
PubMed
Google Scholar
48.
Osgood E, Trudeau JJ, Eaton TA, et al. Development of a bedside pain assessment kit for the classification of patients with osteoarthritis. Rheumatol Int 2015;35:1005–1013.
Crossref
PubMed
Google Scholar
49.
Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 2014;155:367–376.
Crossref
PubMed
Google Scholar
50.
Koulouris AE, Edwards RR, Dorado K, et al. Reliability and validity of the Boston Bedside Quantitative Sensory Testing Battery for Neuropathic Pain. Pain Med 2020; Sep 8:pnaa192.
Crossref
PubMed
Google Scholar
51.
Chen X, Graham J, Dabbah MA, et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes care 2015;38:1138–1144.
Crossref
PubMed
Google Scholar
52.
Perkins BA, Lovblom LE, Bril V, et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia 2018;61:1856–1861.
Crossref
PubMed
Google Scholar
53.
Tavakoli M, Ferdousi M, Petropoulos IN, et al. Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. Diabetes care 2015;38:838–843.
Crossref
PubMed
Google Scholar
54.
Low VA, Sandroni P, Fealey RD, Low PA. Detection of small-fiber neuropathy by sudomotor testing. Muscle & nerve 2006;34:57–61.
Crossref
PubMed
Google Scholar
55.
Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Autonomic evaluation is independent of somatic evaluation for small fiber neuropathy. J Neurol Sci 2014;344:51–54.
Crossref
PubMed
Google Scholar
56.
Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 2013;48:883–888.
Crossref
PubMed
Google Scholar
57.
Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O'Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve 1997;20:1561–1568.
Crossref
PubMed
Google Scholar
58.
Benatar M Distal symmetric polyneuropathy: limitations of the proposed case definition. Muscle Nerve 2006;34:131–134.
Crossref
PubMed
Google Scholar
59.
Botez SA, Herrmann DN. Pitfalls of diagnostic criteria for small fiber neuropathy. Nat Clin Pract Neurol 2008;4:586–587.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 95 • Number 22 • December 1, 2020
Pages: 1005-1014
PubMed: 33055271

Copyright

© 2020 American Academy of Neurology.

Publication History

Received: June 10, 2020
Accepted: September 21, 2020
Published online: October 14, 2020
Published in issue: December 1, 2020

Permissions

Request permissions for this article.

Disclosure

Several authors lead academic or commercial laboratories that process skin biopsies to assess IENFD. Robert H. Dworkin has received in the past 5 years research grants and contracts from the US Food and Drug Administration and the US National Institutes of Health and compensation for serving on advisory boards or consulting on clinical trial methods from Abide, Acadia, Adynxx, Analgesic Solutions, Aptinyx, Aquinox, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Concert, Coronado, Daiichi Sankyo, Decibel, Dong-A, Editas, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Hydra, Immune, Johnson & Johnson, Lotus Clinical Research, Mainstay, Medavante, Merck, Neumentum, Neurana, NeuroBo, Novaremed, Novartis, NSGene, Olatec, Periphagen, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sanifit, Scilex, Semnur, Sollis, Spinifex, Syntrix, Teva, Thar, Theranexus, Trevena, Vertex, and Vizuri. Catharina Faber has received grants from the European Commission, the Prinses Beatrix Spierfonds, Grifols, and Lamepro and consulting income from Biogen, Chromocell, Astellas, and Vertex. Eva L. Feldman has received funding from the NIH (R21NS102924, R24DK082841, R01DK107956, and R01DK108173) and the Novo Nordisk Foundation (NNF14SA0006). In the past 36 months, Roy Freeman has received funding from the NIH (U54NS065736, 1R01NS10584401A1, and R01HL111465-01A1) and personal compensation and/or stock options for serving on scientific advisory boards of Abide, Averitas, Applied Therapeutics, Aptinyx, Biogen, Clexio, Ceracor, Cutaneous NeuroDiagnostics, GW Pharma, Lundbeck, NeuroBo, Pfizer, Regenacy, Spinifex, Toray, Theravance, and Vertex. In the past 36 months, Jennifer Gewandter has received research grants from the NIH and consulting income from MundiPharma, Disarm Therapeutics, Asahi Kasei Pharma, Magnolia Neurosciences, Orthogonal Neurosciences, Science Branding Communications, and SK Life Science. In the past 36 months, Simon Haroutounian has received research grants from Pfizer Inc and Disarm Therapeutics and consulting fees from Medoc Ltd and Rafa Laboratories. Ahmet Hoke received grants from the NIH, DOD, and AMRF. In the past 36 months, Dr. Hoke served as a consultant to Pfizer and currently serves on the Scientific Advisory Board of Disarm Therapeutics. Giuseppe Lauria has received grants from the European Commission, Italian Ministry of Health, Lombardy Foundation for Biomedical Research (FRRB), Lombardy Hub for Research and Innovation, and Italian Foundation for the Research in ALS (AriSLA) and consulting income from CSL Behring, Biogen, Vertex, Chromocell, and Astellas. In the past 36 months, Rayaz Malik has received research grants from QNRF and consulting income from Pfizer, Novo Nordisk, Merck Pharma, and Biogen. Anne Louise Oaklander has received research funding from the NIH (R01NS093653 and R01NS095640), Department of Defense (GW140169 and GW130109), and private foundations. Amanda Peltier has received consulting compensation from Akcea, Alnylam, Catalyst and CSL Behring and has grant funding from the NINDS. Elissa Ritt was employed by NuFactor Specialty Pharmacy at the time of the meeting James W. Russell has received funding from the NIH (1R01DK107007-01A1) and Office of Research Development, Department of Veterans Affairs (101RX001030). Dr. Gordon Smith has received research grants from the NIH (NINDS and NIDDK) and consulting income from Disarm Therapeutics, Regenesis, Alexion, and Argenx. In the past 36 months, Roi Treister has received research grants from the ISF (Israel Science Foundation) and EFIC (European pain federation) and consulting income from Medasense, Medoc, Syqe Medical, and Analgesic Solutions. Nurcan Üçeyler has received research grants from Shire Takeda, Idorsia, Sanofi Genzyme, and Biogen. Go to Neurology.org/N for full disclosures.

Study Funding

This article was funded by the ACTTION public-private partnership.

Authors

Affiliations & Disclosures

Roy Freeman, MD* https://orcid.org/0000-0003-3976-6022
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Akcea, Averitas, Applied Therapeutics, Biogen, Clexio, Ceracor, Cutaneous NeuroDiagnostics, GW Pharma, Lundbeck, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray, Theravance and Vertex.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Autonomic Neuroscience - Basic and Clinical, Editor (2007-2016) Autonomic Neuroscience - Basic and Clinical, Editor-in-Chief (2016-) Clinical Autonomic Research, Editorial Board (1999- present) Clinical Journal of Pain, Assoc. Editor, 2009-2012 Clinical Journal of Pain, Editorial Board (2009-present)
Patents:
1.
NONE
Publishing Royalties:
1.
Royalties from UptoDate
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH (NINDS), U54 NS 065736, Co-PI, 09/30/15- 06/30/2020 (2) NIH (NINDS) 1R01NS10584401A1 (PI) 05/15/2019- 3/31/2024
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Multiple system atrophy consortium
Stock/stock Options/board of Directors Compensation:
1.
Abide, Aptinyx, Cutaneous NeuroDiagnostcs, NeuroBo and Reganacy
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jennifer S. Gewandter, PhD, MPH* https://orcid.org/0000-0001-7938-6775
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) IASP NeuPSig (2017) - travel support for speaker (2) SOPATE 2019 - travel support for speaker
Editorial Boards:
1.
Neuropathic Pain Co-Section editor for Pain Medicine
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Regenacy Pharmaceuticals (2) Mundi Pharmaceuticals (3) MD Anderson (4) Disarm Therapeutics (5) Asahi Kasei Pharma (6) SK Life Science (7) Magnolia Neurosciences (8) Science Branding Consulting (9) Mitobridge (10) MedVal Scientific Information Services
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Neurometrix (2) Pfizer, Simplified Pain Evaluation and Communication Tool utilizing the Electronic Record (SPECTER), Co-PI (2015-2018)
Research Support, Government Entities:
1.
(1) FDA, AWD00001170, Co-investigator (2016-2020) (2) NIH, R21CA235389, PI, (2019-2021) (3) NIH, U24NS113784, MPI, (2019-2024)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) ACTTION public-private partnership
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Catharina G. Faber, MD, PhD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
1. Commercial entities: advisory board for studies in small fibre neuropathy of Biogen/Convergence, Vertex and Lilly
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
European Union
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christopher Gibbons, MD https://orcid.org/0000-0003-0087-5336
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Served on a Scientific Advisory Board for Lundbeck.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Autonomic Neuroscience Basic and Clinical, associate editor 2018-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
RJG Foundation Stock/Stock Options, Medical Equipment & Materials: Stock options in Cutaneous Neurodiagnostics
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Served as an expert witness for the Department of Justice Vaccine Compensation Program.
View all articles by this author
Simon Haroutounian, PhD https://orcid.org/0000-0003-2231-5452
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate Editor - Journal of Pain and Palliative Care Pharmacotherapy, 2017
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Medoc Ltd Rafa Laboratories
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Disarm therapeutics (research support)
Research Support, Government Entities:
1.
NIH/NINDS, R01NS104500-01, 5-HT3 receptor antagonists for neuropathic pain, PI, 12/1/2017-11/30/2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Giuseppe Lauria, MD https://orcid.org/0000-0001-9773-020X
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
GL served on scientific advisory board of Vertex, Biogen, Chromocell, CSL Behring
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor-in-Chief, Journal of the Peripheral Nervous System (2019-)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Todd Levine, MD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Grifols Nufactor
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Corinthian reference labs CND Life Sciences
Consultancies:
1.
Nufactor, Grifols, Malinckrodt
Speakers' Bureaus:
1.
Alexion, Grifols, CSL Behring
Other Activities:
1.
received financial support from NuFACTOR, Inc. during the course of this study
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Grifols, NuFACTOR, Inc.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Rayaz A. Malik, MBChB, PhD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Advisory board for Pfizer on NCD's
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Pfizer Novo Nordisk Merck Pharma Honorarium for speaking
Editorial Boards:
1.
1. Scientific Reports, associate editor 2 years. 2. PLOs One, associate editor 4 years. 3. Diabetic Medicine, associate editor, 8 years
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
J. Robinson Singleton, MD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
Hand held, point-of-care device to test vibration sensory threshold as a diagnostic screen for peripheral neuropathy, for use in primary care screening.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
University of Utah, Professor, Neurology
Consultancies:
1.
Consultant, Reviewer; Medical Review Institute of America, Salt Lake City
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
2R01 DK064814-09A1(Singleton/Smith PIs)04/01/2015 ? 03/31/2021NIH/NIDDKActivity for DiAbetic PolyneuropaThy (the ADAPT Study)Randomized trial comparing standard care to integrated intervention of supervised exercise and actigraphy based sedentary behavior reduction for diabetic neuropathy, using IENFD as co-primary endpoint.Role: Co-Principal Investigator1U01 NS095388-01A1(Smith PI) 6/1/2017- 5/31/2021NIH/NINDS NeuroNEXT Topiramate for Cryptogenic Sensory Polyneuropathy (TopCSPN)Multi-site randomized, double blinded placebo controlled trial of Topiramate in sensory neuropathy associated with metabolic syndrome.Role: Co-Investigator1U01 AR070498 (Amato/Carrillo PIs)9/01/17 ? 4/30/23NIH/NINDS NeuroNEXT Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE Myopathy (MaGiNE trial) NN-109Multisite DBRCT running through the NINDS Neuro-NEXT networkRole: Site Principal InvestigatorNIH/NCATS UL1-TR001067 And TL1TR001066 (Dere/Hess PIs) 3/1/2018 ? 2/28/2023 University of Utah Center for Clinical and Translational ScienceProvide support to investigators in performance of human subject studies across the spectrum of translational science.Role: Director, CCTS Clinical Trial Services Foundation, Director, TINetwork Hub Liaison Team1U10NS077305-01(Singleton PI) 8/1/2018 - 7/31/2023NIH/NINDSThe Utah Regional Center for Excellence in Neuroscience Clinical Trials (UR-NEXT)Consortium for performance of multicenter clinical trials focused on neurological disease.Role: Site Principal InvestigatorResearch Support, Foundations and Societies: Larry H Miller Foundation (Singleton PI)10/1/2018 ? 3/31/2020Sensitive diagnostic screening and exercise based intervention for Metabolic Syndrome associated Polyneuropathy (MSP) Seed grant to validate reliability of Utah Early Neuropathy Scale when performed primary care medical assistants. Role: Principal Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
A. Gordon Smith, MD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Regenesis Data Monitoring Committee Disarm Therapeutics Study Steering Committee Co-Chair Eidos DSMB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Continuum Editorial Board Annals of Clinical and Translational Neurology Editorial Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Regenesis (2) Disarm Therapeutics (3) Alexion (4) Argenx
Speakers' Bureaus:
1.
(1) Alexion
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) DK064814 PI 2004-2020 NIDDK (2) U01NS0953880 PI 2017-2021 NINDS
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Josh Bell, MD, PhD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Medical Director, Clinical Development, Biogen, 3 years
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Hold restricted stock options in Biogen Inc.
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robert H. Dworkin, PhD https://orcid.org/0000-0002-9464-5488
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Analgesic Solutions, Clexio, Eli Lilly, MMS Holdings, Novaremed, Pfizer, NeuroBo, Regenacy, Vertex
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
please see list below under Consultancies, which included reimbursement of travel expenses for in-person meetings.
Editorial Boards:
1.
(1) Pain, Associate Editor, 2005-present; (2) Journal of Pain, Editorial Board, 2007-present; (3) Canadian Journal of Pain, Editorial Board, 2016-present.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
University of Rochester, Professor, 1997-present.
Consultancies:
1.
Abide, Acadia, Adynxx, Analgesic Solutions, Aptinyx, Aquinox, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Collegium, Concert, Coronado, Daiichi Sankyo, Decibel, Dong-A, Editas, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Hydra, Immune, Johnson & Johnson, Lotus Clinical Research, Mainstay, Medavante, Merck, Neumentum, Neurana, NeuroBo, Novaremed, Novartis, NSGene, Olatec, Periphagen, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sanifit, Scilex, Semnur, SK Life Sciences, Sollis, Spinifex, Syntrix, Teva, Thar, Theranexus, Trevena, Vertex, Vizuri
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, and Opportunities (ACTTION)public-private partnership with the FDA
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, and Opportunities (ACTTION)public-private partnership with the FDA has received unrestricted support from multiple pharmaceutical and device companies, philanthropy, and royalties. A list of current industry sponsors is available at www.acttion.org/partners.
Research Support, Government Entities:
1.
Current funding, all as Principal Investigator: [1] FDA, U01 FD005936-01 (9/15/16-8/31/21): Analgesic, anesthetic, and addiction clinical trial translations, innovations, opportunities, and networks (ACTTION) public-private partnership
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Reckitt-Benckiser Australia, expert witness, 2017-2018
View all articles by this author
Eva Feldman, MD, PhD https://orcid.org/0000-0002-9162-2694
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Jama Neurology, editorial board, 2014-present Editor-on-Chief, Contemporary Neurology Series, 2016-current Nature Neurology, Neurobiology of Disease, Experimental Neurology, editorial board, 2012
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Novartis, 2019-2020, consultant
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Centers for Disease Control, Contract #200-2013-56856, PI, 09/01/2013-08/31/2017, (2) NIH (Prime: Emory University), RO1 NS077982, PI, 09/02/2012-07/31/2016 (3) NIH/NINDS, T32 NS07222, PI, 07/01/2012-06/30/2017 (4) NIH, 1DP3DK094292, PI, 09/30/2011-09/29/2016 (5) NIH-NIDDK (CDC Contract #200-2010-35171; Prime: Wake Forest University (WFUHS 30225)), Site PI, 09/30/2010-09/29/2015 (6) NIH/NIDDK, 1 R24 082841, PI, 04/01/2010-03/31/2016 (7) NIH/NINDS, R01 NS08230401A1, Co-I, 05/01/2014-04/30/2019 (8) NIH (Prime; Direct-University of Colorado, Denver), PI, 06/01/2013-05/31/2017 (9) NIH/NINDS, K23 NS079417, Sponsor, 07/01/13-06/30/18
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Novo Nordisk Foundation, NNF14SA0006, PI, (2) Juvenile Diabetes Research Foundation, Sponsor, (3)Juvenile Diabetes Research Foundation, PI, (4) US-Israel Binational Science Foundation, PI, (5) American Diabetes Association, PI (6) ALS Association, PI
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David N. Herrmann, MBBCh
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
unrelated to the present study (1)Acceleron, Inc - unrelated to present study. (2)Alnylam (Unrelated) (3)Neurogene (Unrelated) (4)Regenacy (Unrelated)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Preceding 24 months. All unrelated. (1) Acceleron Pharma(Consultant. Unrelated to present manuscript) (2) Guidepoint Global (3) Gerson Lehrman Group (4) Slingshot Insights (5) Clear View Health Partners (6) Trinity Partners (7) Cydan (8)Schlesinger (9) Human First Therapeutics (10)Narrow River Management (11)Sarepta (Unrelated)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
Although this is not a study guideline or practice parameter I disclose that I direct an academic, clinical skin biopsy laboratory for assessment of epidermal nerve fiber density and small fiber neuropathy diagnosis. Approximately 20% effort.
Research Support, Commercial Entities:
1.
Site PI. A Phase 2 Randomized, Double-Blind, Placebo- Controlled Study of ACE-083 in Patients with Charcot- Marie Tooth Disease Types 1 and X. Acceleron Pharma, Inc.
Research Support, Government Entities:
1.
Site PI, Inherited Neuropathy Consortium NINDS-2U54 NS065712. PI. The ACT-CMT study. NINDS. 1U01NS109403-02 Site PI. NIDDK. The Effect of high intensity interval training and surgical weight loss on distal symmetric polyneuropathy outcomes R01DK115687 Site Investigator.NeuroNEXT: Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN) NINDS. U01NS077265
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Friedreich's Ataxia Research Alliance Charcot Marie Tooth Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
(1)Outcome Measure, through Copyright to University of Rochester. Unrelated to the present publication.
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ahmet Hoke, MD, PhD https://orcid.org/0000-0003-1215-3373
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
1. Non-profit: Foundation for Peripheral Neuropathy; Scientific Advisory Board 2. Commercial: AxoProtego Therapeutics; Scientific Advisory Board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor-in-Chief, Experimental Neurology Associate editor, Annals of Clinical Translational Neurology
Patents:
1.
1. Patent for the use of ethoxyquin to prevent neuropathy 2. Patent for electro spun fiber mesh to help nerve regeneration
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Johns Hopkins University, Professor
Consultancies:
1.
(1) Commercial: Pfizer (2) Commercial: Galapagos
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH R01 NS091260 (role: PI); DOD OR160032 (role: PI)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Foundation for peripheral neuropathy The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
National Vaccine Injury Program: gave expert testimony on GBS Arnold & Porter Kaye Scholer LLP: gave expert testimony on peripheral neuropathy
View all articles by this author
Noah Kolb, MD https://orcid.org/0000-0003-2651-2349
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1. Disarm therapeutics
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. NIH KL2, #1KL2TR001065, PI, 2014-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Lake Champlain Cancer Research Organization, PI 2017-2018
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Heikki Mansikka, MD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Orion Pharma, Clinical Development Head, 0.5 yearVertex Pharmaceuticals, Senior Medical Director, 1 yearChromocell Corp, Vice President, 2 years
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
Vertex Pharmaceuticals
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anne Louise Oaklander, MD, PhD https://orcid.org/0000-0002-9578-1596
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Non-profit entity Scientific Advisory Board: Pain Research Forum
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurology® Neuroimmunology & Neuroinflammation, Associate Editor 2020- Canadian Journal of Pain Editorial Board 2016-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
Director Mass. General Hospital Peripheral Nerve Unit, NeuroSkin Biopsy Lab
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
2015-2019 Department of Defense GW140169 Diagnosis of late-stage, early- onset, small-fiber polyneuropathy. Principal Investigator 2015–2021 NIH R01NS093653. Evaluation of small-fiber polyneuropathy as a cause of chronic widespread pain in youth. Principal Investigator 2016–2021 NIH R01 NS095640 mRNA Splicing Modulation in Familial Dysautonomia Co-investigator (Principal Investigator Susan A. Slaugenhaupt) 2020–2025 NIH 2 R01 NS093653-06 Evaluation of small-fiber polyneuropathy in youth. Principal Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The MayDay Fund 2019-2021 NextGen|HSN-Precision medicine for early stage genetic small-fiber polyneuropathy. Principal Investigator
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Amanda Peltier, MD https://orcid.org/0000-0003-1097-7715
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Advisory board for CSL Behring, Alnylam, Akcea, Catalyst Pharmaceutical Co
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel for sponsored grand rounds by Akcea at University of Mississippi, Medical University of South Carolina
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Investigator Initiated study for CSL Behring funded.PI for Akcea study
Research Support, Government Entities:
1.
NIH, NINDS, Neuronext NN108
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Secretary IDNC Board of PNS, Board of American Autonomic Society
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael Polydefkis, MD https://orcid.org/0000-0002-7584-7447
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Pfizer, Ionis Pharmaceuticals and Alnylam
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Commercial: Pfizer, Ionis Pharmaceuticals and Alnylam
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
As part of his clinical practice Dr. Michael Polydefkis performs NCV/EMG studies (20% effort) and directs the Johns Hopkins Bayview EMG laboratory. He also directs the Johns Hopkins Cutaneous Nerve Laboratory (20% effort).
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Elissa Ritt, DHSc
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Employed at time of consensus meeting by NuFactor Specialty Pharmacy, Medical Science Liaison, 6 years. Currently employed by argenx, two years. Stock/Stock Options, Medical Equipment & Materials: argenx, 2018-present
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
James W. Russell, MBChB
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
Commercial entity: Advisory Board for Akcea therapeutics Non Commercial entity: ACTTION CONCEPPT advisory program to develop outcome measures in diabetic neuropathy.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Copyright applied for the SAS survey by the university of maryland, veterans administration
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIDDK 1R01DK107007-01A1 PI 2016 - present Veterans Administration Merit awards 101RX001030 PI, 2013-present ORD Shared Equipment Evaluation Program (ShEEP), PI, 2017 - present Veterans Administration CDA2: Primary Mentor 2016 - present NIH NINDS 1K08NS102468 - 01A1: Primary Mentor, 2018 - present T32 NIDDK: Co-Investigator, 2015 - present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Stephen Sainati, MD, PhD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Horizon Therapeutics 150 S Saunders Road Lake Forest, IL 60045 Senior Medical Director since 16 MAR 2020
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Deborah Steiner, MD
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) Eli Lilly and Co, Clinical Head Global Development, 0.25 year
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
(1) Sarepta Therapeutics
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Roi Treister, PhD https://orcid.org/0000-0002-5624-2995
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Grunenthal, funding for travel, (2) MEDOC Ltd, funding for travel
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) MEDOC, (2) Analgesic Solutions
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Israel Science Foundation, grant 1437/18.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Nurcan Üçeyler, MD https://orcid.org/0000-0001-6973-6428
From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Genzyme Corp., Shire Corp.
Editorial Boards:
1.
Section Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Genzyme Corp., Shire Corp.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Idorsia, Shire Corp., Genzyme
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Freeman [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Roy Freeman and Jennifer S. Gewandter are co–first authors.
*
These authors contributed equally to this work as co-first authors.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Amanda Chee Yun Chan,
    • Ryan Seng Hong Wong,
    • Nicholas Wen Jie Foo,
    Small Fiber Neuropathy, International Encyclopedia of Public Health, (497-510), (2025).https://doi.org/10.1016/B978-0-323-99967-0.00242-8
    Crossref
    • Daniela Noa Zohar,
    • Daria Keren,
    • Lamis Qassim,
    • Mailam Eltity,
    • Efrat Shavit-Stein,
    • Joab Chapman,
    • Amir Dori,
    Serum neurofilament light chain levels in patients with small-fiber neuropathy, Journal of Neuromuscular Diseases, (2024).https://doi.org/10.1177/22143602241284130
    Crossref
    • Nuri Jacoby,
    • Yaacov Anziska,
    A Practical Approach to Diagnosing Peripheral Neuropathies, Seminars in Neurology, 45, 01, (004-012), (2024).https://doi.org/10.1055/s-0044-1791721
    Crossref
    • Jamie Burgess,
    • Anne Marshall,
    • Leandros Rapteas,
    • David Riley,
    • Kohei Matsumoto,
    • Cheng Boon,
    • Alia Alchawaf,
    • Maryam Ferdousi,
    • Rayaz A. Malik,
    • Andrew Marshall,
    • Stephen Kaye,
    • David Gosal,
    • Bernhard Frank,
    • Uazman Alam,
    Idiopathic Distal Sensory Polyneuropathy and Fibromyalgia Syndrome: A Comparative Phenotyping Study, Pain and Therapy, 13, 6, (1541-1558), (2024).https://doi.org/10.1007/s40122-024-00646-x
    Crossref
    • Jamie Burgess,
    • Anne Marshall,
    • Leandros Rapteas,
    • Kevin J. Hamill,
    • Andrew Marshall,
    • Rayaz A. Malik,
    • Bernhard Frank,
    • Uazman Alam,
    Automated immunohistochemistry of intra‐epidermal nerve fibres in skin biopsies: A proof‐of‐concept study, Journal of the Peripheral Nervous System, 29, 3, (329-338), (2024).https://doi.org/10.1111/jns.12650
    Crossref
    • Anne Louise Oaklander,
    Increasing associations of long-COVID with small-fiber neuropathy, Pain, 165, 9, (e93-e95), (2024).https://doi.org/10.1097/j.pain.0000000000003260
    Crossref
    • Margot Geerts,
    • Janneke G. J. Hoeijmakers,
    • Brigitte A. B. Essers,
    • Ingemar S. J. Merkies,
    • Catharina G. Faber,
    • Mariëlle E. J. B. Goossens,
    Patient satisfaction and patient accessibility in a small fiber neuropathy diagnostic service in the Netherlands: A single-center, prospective, survey-based cohort study, PLOS ONE, 19, 4, (e0298881), (2024).https://doi.org/10.1371/journal.pone.0298881
    Crossref
    • Thierry Gendre,
    • Jean-Pascal Lefaucheur,
    • Tarik Nordine,
    • Yasmine Baba-Amer,
    • François-Jérôme Authier,
    • Jérôme Devaux,
    • Alain Créange,
    Characterizing Acute-Onset Small Fiber Neuropathy, Neurology Neuroimmunology & Neuroinflammation, 11, 2, (2024)./doi/10.1212/NXI.0000000000200195
    Abstract
    • Danyale Berry,
    • Justice Ene,
    • Aakash Nathani,
    • Mandip Singh,
    • Yan Li,
    • Changchun Zeng,
    Effects of Physical Cues on Stem Cell-Derived Extracellular Vesicles toward Neuropathy Applications, Biomedicines, 12, 3, (489), (2024).https://doi.org/10.3390/biomedicines12030489
    Crossref
    • Hoda Gad,
    • Sanjay Kalra,
    • Rizaldy Pinzon,
    • Rey‐an Nino Garcia,
    • Kitiyot Yotsombut,
    • Ankia Coetzee,
    • Jalal Nafach,
    • Lee‐Ling Lim,
    • Pablo E. Fletcher,
    • Vivien Lim,
    • Rayaz A. Malik,
    Earlier diagnosis of peripheral neuropathy in primary care: A call to action, Journal of the Peripheral Nervous System, 29, 1, (28-37), (2024).https://doi.org/10.1111/jns.12613
    Crossref
  11. See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF